Enzolytics Inc (ENZC)

[docsetc]

COMPARATIVE NOTES FOR TODAY:
Gilead's top contender in the mABS market, once bragged upon and pumped endlessly for investors and their biopharma futures, Magolimab, a top cancer fighting product, took a nose dive this week, showing toxicology and a higher likelihood of death set of issues. All Clinical Stage 1 testing has been put on hold. Stage II indefinitely delayed for now.

This Magrolimab product, was Gilead's leading research and product line to begin a large procession of mABS therapeutics and possibly cures. Now its going nowhere after more testing and analysis has been orderd up to see what's next for Gilead.

I hope Dr. Chandra caught sight of this development, one of the potential partnership suitors just hit a wall with their own top mABS therapeutic candidate. Opportunities....

GLTA

https://www.biospace.com/article/gilead-s-magrolimab-ineffective-linked-to-increase-risk-of-death-in-mds-patients/?utm_campaign=Newsletter%20%7C%20GenePool&utm_medium=email&_hsenc=p2ANqtz-8UI3j5puZ2dGw19iNTUUC-hYAA5yf9BLiwm6iOMb9mszDCVjhTUK5EAuohii6iLfj-9OitCLSyYpmmDMLvlzgsXRevSQ&_hsmi=311924366&utm_content=311924366&utm_source=hs_email